M da i Ob aiAcceFda ia CRISPR IP

Modalis Therapeutics and Editas Medicine conclude license
April 1, 2020

TOKYO Modalis Therapeutics Corporation (Modalis) today announced that the company hasentered into a license agreement with Editas Medicine, Inc., under which Modalis has obtained
a license to certain intellectual property that is controlled by Editas Medicine. Modalis isutilizing its proprietary epigenetic gene modulation technology, CRISPR-GNDM (Guide
Nucleotide Directed Modulation), to treat patients with serious genetic disorders. Additional
details including financial terms of the agreement were not disclosed.
"Our goal is to create CRISPR based gene therapies for genetic disorders, most of which fall into
the orphan disease category. There should be no disease that is ignored because of its small
patient population, and our mission to develop disease modifying treatments for these diseases
reflects our belief that ’Every Life Deserves Attention’. We are proud to be the pioneer inCRISPR based gene modulation therapy,” said Haru Morita, Chief Executive Officer of Modalis.
“We are pleased to establish this license agreement with Modalis Therapeutics as their missionis aligned with our mission to make transformative medicines for people living with serious
diseases of unmet clinical need. CRISPR technology has many uses and applications, and we arepleased to include Modalis in our expanding portfolio of licensees so the greatest number ofpatients may benefit in the future from transformative medicines,” said Cynthia Collins,president and chief executive officer, Editas Medicine.
About Modalis
Modalis Therapeutics is developing precision genetic medicines through epigenetic genemodulation. Founded by Osamu Nureki and leading scientists in CRISPR gene editing fromUniversity of Tokyo, Modalis is pursuing therapies for orphan genetic diseases using its
proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene
expression or histone modification without the need for double-stranded DNA cleavage, gene
editing or base editing. Modalis is focusing initially on genetic disorders caused by loss of gene
regulation resulting in excess or insufficient protein production which includes more than
660 genes that are currently estimated to cause human disease due to haploinsufficiency.
Headquartered in Tokyo with laboratories and facilities in Cambridge, Massachusetts, thecompany is backed by leading Japanese investors including Fast Track Initiative, SBI Investment,
UTokyo-IPC, SMBC Venture Capital, and Mizuho Capital. For additional information,
visit www.modalistx.com.

モダリス、CRISPR 基

許のライセンスを獲

モダリス－エディタスでライセンス契

モダリス株会：(京央区しました。

契である CRISPR のへのアクセスを獲する「しむ患開のためのいた遺はをるします。っていることを回のにたちはすることなく、エ患にする遺のミッションである E e

たちは CRISPR による遺技がない

患に苦すのは CRISPR をが患にしてLife De e eたるような開のパイオニアとして開な気に苦しむ患患にする医のようにニーズ)にして革なを開するモダリスとのきることを歓迎しています。CRISPR 技やアプリケーションが回のを救う可携をじてのは々な携ポートフォリオの拡があることを喜んでいます。」

べのアンメット・メディカルニーズることをミッションとしており、このミッションに共し、をっております。」

携についてエディタス CEO であるシンシア・コリンズはなの CRISPR-な遺べております。「我々が患にもりにを) の結したしています。

り、希ております。「我々は(をのようにです。

Attention(すべてのをらない CRISPR」によりにより、そのほとんどが希なををするゲノムします。モダリスはにより、遺)技

ピジェネティックスをモダリス CEO の)との間でライセンス契によってモダリスはエディタスの型遺GNDM(ガイド核、エディタス)はマサチューセッツ

(Editas Medicine Inc.
技結4月1: 2020

ことををし、さらにす

携がでくの患